Evaluation of antidiabetic properties of cactus pear seed oil in rats

Figures & data

Table 1. Changes in blood glucose level variation during 6 h after oral administration of cactus pear seed oil (CPSO) at 1 or 2 ml kg⁻¹ and of glibenclamide at 2 mg kg⁻¹ in healthy rats.

	Time (min)
Treatment	0	30	60	120	240	360
Control	0.89 ± 0.06	1.26 ± 0.06	1.20 ± 0.12	0.97 ± 0.04	0.91 ± 0.02	0.91 ± 0.04
CPSO (1 ml kg^−1)	0.92 ± 0.01	1.32 ± 0.07	1.51 ± 0.14	1.11 ± 0.06	0.99 ± 0.03	0.94 ± 0.03
CPSO (2 ml kg^−1)	0.90 ± 0.02	1.16 ± 0.08	1.07 ± 0.07	1.01 ± 0.04	0.98 ± 0.05	0.95 ± 0.05
Glibenclamide (2 mg kg^−1)	0.93 ± 0.03	1.30 ± 0.09	1.17 ± 0.09	0.99 ± 0.07	0.80 ± 0.06	0.60 ± 0.05*

Values are means ± SEM (n = 6).

*p ≤ 0.001 compared with the control group.

Figure 1. Effects of cactus pear seed oil (CPSO) on glucose plasma level and AUC_glucose in normal rats. Values are means ± SEM (n = 6). *p ≤ 0.05; **p ≤ 0.001; ***p ≤ 0.0001 compared with normal controls.

Figure 2. Effects of cactus pear seed oil (CPSO) on glucose plasma level and AUC_glucose in STZ-induced diabetic rats. Values are means ± SEM (n = 6). **p ≤ 0.001; ***p ≤ 0.0001 compared with diabetic controls.

Figure 3. Effect of cactus pear seed oil (CPSO) on free d-glucose absorption assessed by in situ single-pass intestinal perfusion. Data are means ± SEM (n = 6). *p ≤ 0.05; **p ≤ 0.001 compared with normal controls.